Study Name:
KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)
Targeted Disease(s):
Lung Cancer
Purpose of Study:
Researchers want to learn if study treatments that are antibody drug conjugates (ADCs) can treat metastatic squamous NSCLC that did not respond (get smaller or go away) to standard treatment. The main goals of this study are to learn about 1) the cancer response to the study treatments compared to chemotherapy and 2) the safety of the study treatments and if people tolerate them.
Study Dates:
May 28, 2025 - March 2, 2032
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Sponsors:
Merck Sharp & Dohme LLC
Contact:
Phone: 1-888-577-8839
Email: [email protected]
ClinicalTrails.gov Identifier:
NCT06780098
